

Bone Medical

ASX/MEDIA RELEASE


Results of Annual General Meeting

28 November 2007: Bone Medical Limited (ASX:BNE) Further to the Shareholder meeting held yesterday and in accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and proxies received, these are set out in the proxy summary below.

		For	Against	Open	Abstain
Resolution 1	<i>That shareholders adopt the Remuneration Report</i>	47,430,817	-	228,268	-
Resolution 2	<i>Re-election of Dr Roger New as a Director</i>	47,430,817	-	228,268	-
Resolution 3	<i>Election of Prof Peter Brooks as a Director</i>	47,430,817	-	228,268	-
Resolution 4	<i>Election of Leif Helth Jensen as a Director</i>	47,430,817	-	228,268	-
Resolution 5	<i>Ratification of the issue of 5,412,591 Options</i>	47,087,235	166	228,268	3,333
Resolution 6	<i>Adoption of new constitution</i>	47,090,734	-	228,268	-
Resolution 7	<i>Appointment of Auditor</i>	598,360	-	228,268	46,492,374

All resolutions were passed on a show of hands.

- ENDS -



Bone Medical

Enquiries:

Dr Roger New
Chairman
Mobile: +44 781 806 8012
Australian Office: +61 8 9355 5123

Rudi Michelson
Monsoon Communications
+61 3 9620 3333

Troels Jordansen
Managing Director
Mobile: + 44 79 1713 0019

Or visit: www.bonemedical.com

About Bone Medical Limited

Bone Medical Limited is an international biopharmaceutical development company positioned to exploit the growing market in the treatment of bone disease particularly in osteoporosis and arthritis. Bone has a portfolio of biopharmaceutical development projects for the treatment of bone disease including,

Osteoporosis

- Capsitonin™ oral calcitonin
- Perthoxal™ oral parathyroid hormone
- bone cell regulators BN005 & BN008

Arthritis

- TNF regulators BN006
- joint protection & collagen tolerance BN007